Association between HLA-DRB1 alleles polymorphism and hepatocellular carcinoma: A meta-analysis

BMC Gastroenterology

Volumn 10, Issue , 2010, Pages

  Lin, Zhong Hua ^a,b   Xin, Yong Ning ^b,c   Dong, Quan Jiang ^b   Wang, Qing ^b   Jiang, Xiang Jun ^b   Zhan, Shu Hui ^b   Sun, Ying ^b   Xuan, Shi Ying ^b,c  

^a QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

^b QINGDAO MUNICIPAL HOSPITAL   (China)

^c OCEAN UNIVERSITY OF CHINA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DR ANTIGEN; HLA-DRB1 ANTIGEN;

ARTICLE; ASIAN; CANCER RISK; CANCER SUSCEPTIBILITY; ETHNICITY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; HIGH RISK POPULATION; HUMAN; LIVER CELL CARCINOMA; SYSTEMATIC REVIEW; ALLELE; GENETICS; IMMUNOLOGY; LIVER TUMOR; META ANALYSIS;

ALLELES; CARCINOMA, HEPATOCELLULAR; HLA-DR ANTIGENS; HUMANS; LIVER NEOPLASMS; POLYMORPHISM, GENETIC;

EID: 78650286788     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-10-145     Document Type: Article

References (31)

1. Schutte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma--epidemiological trends and risk factors. Dig Dis 2009, 27:80-92.
2. International Agency for Cancer Research: GLOBCAN 2002. , http://www-dep.iarc.fr
3. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576. 10.1053/j.gastro.2007.04.061, 17570226.
4. Klein J, Sato A. The HLA system. First of two parts. N Engl J Med 2000, 343:702-709. 10.1056/NEJM200009073431006, 10974135.
5. Klein J, Sato A. The HLA system. Second of two parts. N Engl J Med 2000, 343:782-786. 10.1056/NEJM200009143431106, 10984567.
6. Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002, 122:1609-1619. 10.1053/gast.2002.33411, 12016426.
7. Conn VS, Rantz MJ. Research methods: managing primary study quality in meta-analyses. Res Nurs Health 2003, 26:322-333. 10.1002/nur.10092, 12884420.
8. Huwiler-Muntener K, Juni P, Junker C, Egger M. Quality of reporting of randomized trials as a measure of methodologic quality. JAMA 2002, 287:2801-2804. 10.1001/jama.287.21.2801, 12038917.
9. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188. 10.1016/0197-2456(86)90046-2, 3802833.
10. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634. 2127453, 9310563.
11. Donaldson PT, Ho S, Williams R, Johnson PJ. HLA class II alleles in Chinese patients with hepatocellular carcinoma. Liver 2001, 21:143-148. 10.1034/j.1600-0676.2001.021002143.x, 11318984.
12. De Re V, Caggiari L, Talamini R, Crovatto M, De Vita S, Mazzaro C, Cannizzaro R, Dolcetti R, Boiocchi M. Hepatitis C virus-related hepatocellular carcinoma and B-cell lymphoma patients show a different profile of major histocompatibility complex class II alleles. Hum Immunol 2004, 65:1397-1404. 10.1016/j.humimm.2004.08.183, 15556690.
13. Yuan JH, Sun CG. Relationship between every kind of chronic hepatitis B' prognosis and HLA-DRB1 allele in Chinese patients of shandong area. Chin J Clini Hepatol 2004, 20:236-237.
14. Lopez-Vazquez A, Rodrigo L, Mina-Blanco A, Martinez-Borra J, Fuentes D, Rodriguez M, Perez R, Gonzalez S, Lopez-Larrea C. Extended human leukocyte antigen haplotype EH18.1 influences progression to hepatocellular carcinoma in patients with hepatitis C virus infection. J Infect Dis 2004, 189:957-963. 10.1086/382189, 14999597.
15. Yuan JH, Cui M, Sun CG, Yu HL. Association between HLA-DRB1*1201/*1501 and diferent stages of HBV infection. J Shandong University 2005, 43:428-431.
16. Kummee P, Tangkijvanich P, Poovorawan Y, Hirankarn N. Association of HLA-DRB1*13 and TNF-alpha gene polymorphisms with clearance of chronic hepatitis B infection and risk of hepatocellular carcinoma in Thai population. J Viral Hepat 2007, 14:841-848.
17. El-Chennawi FA, Auf FA, Metwally SS, Mosaad YM, El-Wahab MA, Tawhid ZE. HLA-class II alleles in Egyptian patients with hepatocellular carcinoma. Immunol Invest 2008, 37:661-674. 10.1080/08820130802111605, 18821214.
18. Pan HF, Li DF, Sun TH, Wang XJ. Association of HLA-DRB1 gene polymorphism and expression of DR antigen with primary hepatocellular carcinoma. Chin J Hepatobiliary Surg 2009, 15:357-361.
19. Thio CL, Thomas DL, Carrington M. Chronic viral hepatitis and the human genome. Hepatology 2000, 31:819-827. 10.1053/he.2000.4316, 10733534.
20. Aikawa T, Kojima M, Onishi H, Tamura R, Fukuda S, Suzuki T, Tsuda F, Okamoto H, Miyakawa Y, Mayumi M. HLA DRB1 and DQB1 alleles and haplotypes influencing the progression of hepatitis C. J Med Virol 1996, 49:274-278. 10.1002/(SICI)1096-9071(199608)49:4<274::AID-JMV3>3.0.CO;2-0, 8877758.
21. Yang G, Liu J, Han S, Xie H, Du R, Yan Y, Xu D, Fan D. Association between hepatitis B virus infection and HLA-DRB1 genotyping in Shaanxi Han patients in northwestern China. Tissue Antigens 2007, 69:170-175. 10.1111/j.1399-0039.2006.00744.x, 17257320.
22. Zhang SY, Gu HX, Li D, Yang SF, Zhong ZH, Li XK, Jin X. Association of human leukocyte antigen polymorphism with hepatitis B virus infection and genotypes. Jpn J Infect Dis 2006, 59:353-357.
23. Amarapurpar DN, Patel ND, Kankonkar SR. HLA class II genotyping in chronic hepatitis B infection. J Assoc Physicians India 2003, 51:779-781.
24. Godkin A, Davenport M, Hill AV. Molecular analysis of HLA class II associations with hepatitis B virus clearance and vaccine nonresponsiveness. Hepatology 2005, 41:1383-1390. 10.1002/hep.20716, 15915462.
25. Yang YC, Chang TY, Lee YJ, Su TH, Dang CW, Wu CC, Liu HF, Chu CC, Lin M. HLA-DRB1 alleles and cervical squamous cell carcinoma: experimental study and meta-analysis. Hum Immunol 2006, 67:331-340. 10.1016/j.humimm.2006.03.017, 16720214.
26. Delgado-Vega AM, Anaya JM. Meta-analysis of HLA-DRB1 polymorphism in Latin American patients with rheumatoid arthritis. Autoimmun Rev 2007, 6:402-408. 10.1016/j.autrev.2006.11.004, 17537386.
27. Castano-Rodriguez N, Diaz-Gallo LM, Pineda-Tamayo R, Rojas-Villarraga A, Anaya JM. Meta-analysis of HLA-DRB1 and HLA-DQB1 polymorphisms in Latin American patients with systemic lupus erythematosus. Autoimmun Rev 2008, 7:322-330.
28. Duarte-Rey C, Pardo AL, Rodriguez-Velosa Y, Mantilla RD, Anaya JM, Rojas-Villarraga A. HLA class II association with autoimmune hepatitis in Latin America: a meta-analysis. Autoimmun Rev 2009, 8:325-331. 10.1016/j.autrev.2008.11.005, 19041429.
29. Stokkers PC, Reitsma PH, Tytgat GN, van Deventer SJ. HLA-DR and -DQ phenotypes in inflammatory bowel disease: a meta-analysis. Gut 1999, 45:395-401. 10.1136/gut.45.3.395, 1727649, 10446108.
30. Rojas OL, Rojas-Villarraga A, Cruz-Tapias P, Sanchez JL, Suarez-Escudero JC, Patarroyo MA, Anaya JM. HLA class II polymorphism in Latin American patients with multiple sclerosis. Autoimmun Rev 2010, 9:407-413. 10.1016/j.autrev.2009.11.001, 19896562.
31. Zhang XM, Wang HY, Luo YY, Ji LN. HLA-DQ, DR allele polymorphism of type 1 diabetes in the Chinese population: a meta-analysis. Chin Med J (Engl) 2009, 122:980-986.